Illumina Tops Q2 Estimates and Lifts Full-Year Outlook on Robust NovaSeq X Demand

summarizeSummary

Illumina reported Q2 2026 revenue of $1.16 billion, up 9.5% year-over-year, and raised its full-year revenue and earnings guidance. The beat was driven by strong NovaSeq X demand and expanding clinical sequencing applications.

check_boxKey Events · Earnings and Guidance · ILMN

• Q2 Revenue and EPS Beat

  Revenue of $1.16 billion grew 9.5% YoY, exceeding the $1.13 billion consensus. Non-GAAP diluted EPS of $1.31 beat expectations.

• Full-Year Guidance Raised

  FY2026 revenue guidance increased to $4.60-$4.64 billion (from $4.52-$4.62 billion). Non-GAAP EPS guidance raised to $5.30-$5.40 (from $5.15-$5.30).

• NovaSeq X Demand Drives Growth

  Management highlighted high demand for NovaSeq X as clinical customers expand sequencing-intensive applications, driving 8.1% ROW organic revenue growth.

• Strong Cash Position

  Cash, cash equivalents, and short-term investments totaled $1.17 billion at quarter-end, providing ample liquidity for operations and the ongoing $1.5 billion share repurchase program.

auto_awesomeAnalysis · ILMN · Industrial Applications And Services

A clean beat-and-raise quarter underscores Illumina's accelerating momentum. Revenue of $1.16 billion surpassed the $1.13 billion consensus, while adjusted EPS of $1.31 exceeded expectations. Bolstered by strong NovaSeq X demand and expanding clinical applications, management raised full-year revenue guidance to $4.60–$4.64 billion and non-GAAP EPS to $5.30–$5.40. The stock is trading near its 52-week high, reflecting market confidence in the turnaround story after a turbulent period. This report reinforces the narrative that organic growth is accelerating and margins are improving.